GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » EV-to-Revenue

OncoSec Medical (OncoSec Medical) EV-to-Revenue : (As of Apr. 29, 2024)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, OncoSec Medical's enterprise value is $-0.22 Mil. OncoSec Medical's Revenue for the trailing twelve months (TTM) ended in Jan. 2023 was $0.00 Mil. Therefore, OncoSec Medical's EV-to-Revenue for today is .

The historical rank and industry rank for OncoSec Medical's EV-to-Revenue or its related term are showing as below:

ONCSQ's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), OncoSec Medical's stock price is $0.0003. OncoSec Medical's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2023 was $0.00. Therefore, OncoSec Medical's PS Ratio for today is .


OncoSec Medical EV-to-Revenue Historical Data

The historical data trend for OncoSec Medical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical EV-to-Revenue Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's EV-to-Revenue

For the Biotechnology subindustry, OncoSec Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's EV-to-Revenue falls into.



OncoSec Medical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

OncoSec Medical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-0.218/0
=

OncoSec Medical's current Enterprise Value is $-0.22 Mil.
OncoSec Medical's Revenue for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (OTCPK:ONCSQ) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

OncoSec Medical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0003/0
=

OncoSec Medical's share price for today is $0.0003.
OncoSec Medical's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000

OncoSec Medical (OncoSec Medical) Headlines

From GuruFocus

OncoSec Provides Leadership Update

By PRNewswire PRNewswire 08-16-2021